ClinicalTrials.gg
Active, not recruitingNCT05090371SOSTOSUpdated May 29, 2026

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

A Phase 4 interventional study of Ofatumumab and Disease modifying treatment (DMT) in Relapsing-Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 43 sites in 2 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Novartis.

Enrollment
15th of 26
136 · median 147
Started
2022
with 1 other
Phase 4
15 of 34
1 open now
Registered
27th of 34
by date

Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 15th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 in phase 4, and was the 27th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

1 of the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, or all of them as a file.
02

Study summary

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.

Read the detailed description

This is a multicenter, prospective study of up to 150 relapsing-remitting MS participants/ The study is looking to see if patients who have not had a relapse in the past year would benefit from switching to ofatumumab.

After giving consent, participants will have a 1 week screening/qualification period. If they qualify to continue, they will start a a six month run-in period during which lab samples will be collected. Patients that are relapse-free during the run-in period will continue into next period of the study in which they will be randomized to either ofatumumab or continued therapy for the next 15 months. Every 3 out of 5 randomized participants will be selected to wear a digital study watch to collect physical activity, sleep, and vitals during this 15 month period. The study watch will be worn 24 hours a day, 7 days a week but can be removed during showers/bathing. At the end of the 15 month period, a study completion visit will be held.

The total study duration is 21 months plus 1 week for screening/qualification.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis

Keywords

  • Ofatumumab
  • Multiple Sclerosis
  • Relapsing-Remitting Multiple Sclerosis
  • adult
  • OMB157
  • RRMS
  • MS
  • secondary progressive MS
  • relapse
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Age 18-45 years
  • Diagnosis of RRMS per McDonald Criteria (2017)
  • EDSS 0-5.5 (Inclusive)
  • Able to obtain MRI and attend study visits at sites
  • Willing to use wearable device as specified in the protocol
  • Able to provide blood sample
  • On a current DMT with approved label use for treatment of RRMS at least 6 months prior to Screening
  • No relapse reported within 6 months prior to Screening
  • Patients may enroll in the trial if they have subclinical disease activity as measured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.

Exclusion criteria

Exclusion Criteria:

  • Primary progressive or secondary progressive phenotype
  • Diseases other than multiple sclerosis responsible for the clinical or MRI presentation
  • Use of experimental or drugs for MS within 2 years from Screening
  • Known sensitivity to gadolinium
  • Central Nervous System (CNS) anomalies that are better accounted for by another disease process
  • Known active
  • Active chronic disease (or stable but treated with immune therapy) of the immune system other than MS
  • Active infections including systemic bacterial, viral (including COVID-19) or fungal infections, known to have AIDS or tested positive for antibodies
  • Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML), or confirmed PML
  • IgG or IgM levels below lower limit of normal (LLN) at Screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Ofatumumab

    20 mg

    Drug: Ofatumumab

  • Active comparator
    DMT continued therapy

    Participants randomized to the continued therapy arm will continue to take their disease modifying treatment (DMT) as prescribed commercially by their physician.

    Drug: Disease modifying treatment (DMT)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving NEDA-3 (No Evidence of Disease Activity-3)

    A participant is considered as achieved NEDA-3 if the participant has not had a clinical relapse (recurrence of a disease activity after a recovery), has not had an increase in disability and has no new radiological MRI activity (no new occurrences of contrast-enhancing lesions) during study Months 3 to 15.

    Time frame: Months 3 to 15

Secondary outcomes

  1. Percentage of participants with a single baseline NfL≥10pg/ml and NfL<10pg/ml achieving NEDA-3 (No Evidence of Disease Activity-3)

    Participants with a single baseline NfL≥10 pg/ml and NfL\<10pg/ml will be considered as achieved NEDA-3 if the participant has not had a clinical relapse (recurrence of a disease activity after a recovery), has not had an increase in disability and has no new radiological MRI activity (no new occurrences of contrast-enhancing lesions)

    Time frame: Months 3 to15

  2. Annualized relapse rate in Months 3 to 15

    Relapses are recurrences of a disease activity after a recovery. A confirmed MS relapse is one accompanied by a clinically relevant change in the EDSS performed by the EDSS Rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores (FSs) or 2 points on one FS, excluding changes involving bowel/bladder or cerebral FS compared to the previous available rating (the last EDSS rating that did not occur during a relapse). Confirmation of MS relapse based on these definitions will be done centrally.

    Time frame: Months 3 to 15

  3. Percentage of participants without a worsening of their disability

    No increase or worsening of disability

    Time frame: Months 3 to 15

  4. Percentage of participants with NEDA (No Evidence of Disease Activity) - Clinical

    A participant is considered as achieved NEDA-clinical is no clinical relapse or disease progression (by EDSS) has occurred.

    Time frame: Months 3 to 15

  5. Percentage of participants with NEDA (No Evidence of Disease Activity) - Radiological

    A participant is considered as achieved NEDA-radiological if the participant has has no new radiological MRI activity (no new occurrences of contrast-enhancing lesions) during study Months 3 to 15.

    Time frame: Months 3 to 15

  6. Mean change in The Symbol-Digit Modality Test

    This test measures cognition in patients with MS. Patients are asked to substitute a number, either orally or written, for randomized presentations of geometric figures.

    Time frame: Baseline, Months 3 and 15

  7. Mean change in the Time 25 Foot Walk

    This is a test of mobility and leg function. The patient is instructed to one end of a marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time to complete the test is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. The task is performed again when the patient is directed to walk back the same distance. A walking device is permitted during this test.

    Time frame: Baseline, Months 3 and 15

  8. Mean change in the 9 Hole Peg Test

    This is a test of upper extremity function. The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes. The patient picks up the nine pegs one at a time as quickly as possible, puts them in nine holes and once they are in the holes, the patient removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded. This test is performed with both the dominant and non-dominant hand.

    Time frame: Baseline, Months 3 and 15

  9. Mean change in Gd+ lesion count

    Increase in the number of contrast-enhancing lesions on MRI

    Time frame: Baseline, Months 3 and 15

  10. Mean change in Gd+ lesion volume

    Increase in size of contrast-enhancing lesions on MRI

    Time frame: Baseline, Months 3 and 15

  11. Mean change in T2 lesion count

    Increase in new T2 lesions on MRI

    Time frame: Baseline, Months 3 and 15

  12. Mean change in T2 lesion volume

    Increase in size of T2 lesions on MRI

    Time frame: Baseline, Months 3 and 15

  13. Mean change from Baseline in T1

    Presence of new or enlarged T1 lesions

    Time frame: Baseline up to Month 15

  14. Mean change in MSQOL-54

    The MSQOL-54 is health-related quality of life questionnaire that assesses the physical, mental, and social effects experienced by MS patients, as well as functional disability. It is made up for 54 questions with a total score ranging from.0 to 100. Higher scores indicate better quality of life.

    Time frame: Month 3 to Month 15

  15. Mean whole brain and regional volume loss from Baseline

    Brain volume loss is a marker of progressive loss of brain structure and function. It is a predictor of disability progression.

    Time frame: Baseline up to Month 15

  16. Percentage of participants reporting treatment emergent adverse events (TEAEs) and serious adverse events

    Adverse events (TEAEs) and serious adverse events will be reported at each visit

    Time frame: Baseline up to Month 15

07

Study locations

43 sites
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Apr 2027, 61 months after the start.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Oct 22, 2021
StartActual
Mar 2, 2022
Primary completionEst.
Apr 13, 2027
CompletionEst.
Apr 13, 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05090371
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Mar 2, 2022
Primary completion
Apr 13, 2027 (estimated)
Completion
Apr 13, 2027 (estimated)
Last update
May 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ofatumumab

Start the discussion